MedTrace Logo

Incretin Hormones in Type 1 Diabetes Mellitus;Effect of Metformin Treatment

NCT04177303 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2020-02-18

No results posted yet for this study

Summary

Investigators aim is to conduct an RCT to study the effect of adjunct metformin treatment to insulin monotherapy in patients with type 1 diabetes, targeting the intestinal incretin secretion. The patients will be randomly allocated to metformin or placebo treatment for 4 months

Conditions

  • Type 1 Diabetes Mellitus

Interventions

DRUG

Metformin

Participants will be randomized to metformin 2000 mg

DRUG

Placebo

Participants will be randomized to placebo

Sponsors & Collaborators

  • Hellenic Institute for the Study of Sepsis

    lead OTHER

Principal Investigators

  • Kotsa Kalliopi, MD,PhD · 1st Internal Medicine Department, AHEPA University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-29
Primary Completion
2022-11-29
Completion
2022-11-29

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04177303 on ClinicalTrials.gov